LipoScience, Inc. Research Sheds Light on Novel Markers Via Nuclear Magnetic Resonance (NMR) Spectroscopy
Published: Aug 01, 2013
RALEIGH, N.C., July 31, 2013 /PRNewswire/ -- Researchers from LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized NMR diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, are presenting two posters today that highlight the utility of the company's proprietary nuclear magnetic resonance (NMR) technology in measuring novel markers of systemic inflammation, as well as in diagnosing diabetes through measurement of blood glucose. The posters, which will be presented during the Technology/Design Development session at the American Association of Clinical Chemistry (AACC) annual meeting in Houston, Tex., will be on display today from 9:30 a.m. to 5:00 p.m.
GlycA and GlycB: Novel Markers of Systemic Inflammation
In one poster (#B-255), James Otvos and colleagues at LipoScience will present data on two novel markers of systemic inflammation, GlycA and GlycB that were derived from stored serum NMR spectra. Data collected at baseline from 5,680 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) showed that GlycA and GlycB levels were associated with C-reactive protein (CRP, r~0.5-0.6) and fibrinogen, two acute-phase proteins that are commonly used to assess and monitor both acute and chronic inflammation. GlycA was also associated, independent of traditional risk factors, with future (6-year follow-up) coronary heart disease (CHD) events as well as with diabetes, all-cause death, and cancer.
"These data suggest that measurement of GlycA and GlycB via NMR spectroscopy can provide an assessment of inflammation status that is similar or complementary to existing inflammatory biomarkers, thereby aiding in risk assessment for inflammation-mediated cardiovascular disease," stated Dr. Otvos, who is Chief Scientific Officer at LipoScience. "Moreover, these novel markers of inflammation can be detected from NMR LipoProfile test spectra, which can further illuminate a patient's cardiovascular disease risk profile through quantification of lipoprotein particles in a blood sample."
High-Throughput Measurement of Serum Glucose in the Clinical Laboratory by NMR
In the second poster (#B-245), Dr. Thomas O'Connell and colleagues will demonstrate how a blood glucose assay, developed using NMR technology for LipoScience's Vantera® Clinical Analyzer, can enable high-throughput measurement of glucose to aid in the diagnosis of diabetes and pre-diabetes. When comparing glucose measurements made by NMR to those made by a standard chemistry assay, the investigators reported an excellent correlation between methods.
"While the fully automated Vantera Clinical Analyzer is currently used for measurement of lipoprotein particle concentrations, the information-rich nature of the NMR spectrum enables other clinically valuable metabolites such as glucose to be measured in the same spectrum," explained Dr. O'Connell. "Our results highlight the suitability of NMR for high-throughput automated quantification of glucose, which may facilitate diagnosis of diabetes and pre-diabetes."
These presentations follow data recently presented at the 2013 American Diabetes Association annual meeting on the company's research version of an NMR-based diabetes risk index to stratify a patient's risk of developing type 2 diabetes. The data showed that high-risk patients may receive the benefit of more timely and focused clinical interventions intended to slow or prevent the progression to diabetes. The test provides researchers and clinicians with the means to help distinguish those individuals with a higher versus lower likelihood of progressing to type 2 diabetes at any given level of fasting plasma glucose (FPG) or glycosylated hemoglobin (HbA1c).
"The studies presented at AACC support our vision for NMR diagnostics to become standard of care in the management of cardiovascular, metabolic and inflammatory diseases," said Richard O. Brajer, chief executive officer of LipoScience. "These data add to the growing body of evidence and clinical utility of NMR-based assays in terms of more accurate and precise risk management, which may ultimately yield improved patient outcomes."
For more information about the posters and LipoScience's NMR technology, please visit LipoScience, Inc. at booth 5535.
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company's first proprietary diagnostic test, the NMR LipoProfile®test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 10 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera®, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.
LipoScience is driving NMR diagnostics toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the Company's plans, objectives, expectations (financial and otherwise) or intentions. These forward-looking statements include statements about the Company's expectations for the future demand for its products and the factors that drive such demand. Actual results may differ significantly from those projected or suggested in any forward-looking statements. Further information on potential factors and other risks that could affect the Company's business and operating results is included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and other filings the Company makes with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations page of the Company's website at http://investor.liposcience.com/. The statements made herein are based on information available to LipoScience as of the date of this press release, and the Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
SOURCE LipoScience, Inc.
Help employers find you! Check out all the jobs and post your resume.